Company Overview
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Recent Developments
- Dec 2025 Revenue of $52.84M (+9.9% YoY); net profit $-11.21M.
- Trailing 12 Months Year-on-year growth — revenue +22.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.30% |
| 1 Year: | 22.10% |
Stock Price Performance
| 1 Year: | +29.79% |
| 6 Months: | -11.08% |
| 3 Months: | -36.06% |
| 1 Month: | -24.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross5d ago
- RSI (14)36.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 37.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APYX Apyx Medical Corporation PHARMA | 3.05 | -15.25 | $128.48M | 0.00% | -11.69% | -90.69% | 4.30% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 3.40M | 3.69M | 3.67M | 5.84M | 5.63M | 6.65M | 7.58M | 8.38M | 5.00M | 4.30M | 6.95M | 8.64M | 11.22M | 11.83M | 12.49M | 10.29M | 9.11M | 12.14M | 13.57M | 11.98M | 10.24M | 12.15M | 11.49M | 9.43M | 11.37M | 12.88M | 12.49M | 13.88M |
| Gross Profit | 2.67M | 3.14M | 3.23M | 3.51M | 3.32M | 4.70M | 5.06M | 4.83M | 777.00K | 1.57M | 1.91M | 2.70M | 2.21M | 2.54M | 2.52M | 3.56M | 3.56M | 4.67M | 5.29M | 5.56M | 2.98M | 2.09M | 4.72M | 5.86M | 7.53M | 8.06M | 8.22M | 6.91M | 5.76M | 7.57M | 9.28M | 7.98M | 5.95M | 7.49M | 6.95M | 5.67M | 7.08M | 8.30M | 7.92M | 8.87M |
| Operating Income | -2.27M | -1.55M | -1.81M | - | -1.99M | -510.00K | -245.00K | - | -1.74M | -1.31M | -2.83M | - | -2.72M | -2.93M | -2.79M | - | -5.73M | -4.42M | -4.76M | - | -7.49M | -6.17M | -4.37M | -4.75M | -4.04M | -3.97M | -5.87M | -5.98M | -5.78M | -5.61M | -1.24M | -4.64M | -6.62M | -5.55M | -3.63M | -3.05M | -2.57M | -832.00K | -911.00K | -1.81M |
| Net Income | -876.00K | -1.50M | -1.59M | -1.41M | -1.94M | -519.00K | -965.00K | - | -1.69M | -1.31M | -2.94M | - | -2.79M | -2.94M | 68.47M | - | -4.68M | -4.34M | -4.37M | - | -1.95M | -4.69M | -3.73M | -4.90M | -4.05M | -4.22M | -5.95M | -5.43M | -5.76M | -3.48M | -994.00K | -4.63M | -7.58M | -6.56M | -4.70M | -4.15M | -3.78M | -1.98M | -2.11M | -3.24M |
| Diluted EPS | 0.57 | -0.06 | -0.06 | -0.05 | -0.07 | -0.02 | -0.04 | - | -0.06 | -0.04 | -0.04 | - | -0.03 | -10.00 | 1.96 | - | -0.14 | -0.13 | -0.13 | - | - | -0.14 | -0.11 | -0.14 | -0.12 | -0.12 | -0.17 | -0.16 | -0.17 | -0.10 | -0.03 | -0.13 | -0.22 | -0.19 | - | - | - | - | - | - |
| R&D Expense | 446.00K | 505.00K | 583.00K | - | 668.00K | 592.00K | 681.00K | - | 709.00K | 696.00K | 487.00K | - | 514.00K | 763.00K | 613.00K | - | 730.00K | 888.00K | 1.02M | - | 980.00K | 975.00K | 1.05M | 1.11M | 1.08M | 1.18M | 1.16M | 1.07M | 1.06M | 1.27M | 1.36M | 1.41M | 1.40M | 1.42M | 1.14M | 804.00K | 824.00K | 801.00K | 765.00K | 793.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.95M | 24.23M | 25.41M | 27.67M | 23.66M | 27.68M | 29.52M | 8.82M | 10.23M | 16.61M | 28.23M | 27.71M | 48.52M | 44.51M | 52.35M | 48.10M | 52.84M |
| Gross Profit | 11.86M | 9.99M | 10.73M | 11.33M | 9.20M | 8.99M | 12.56M | 5.12M | 6.96M | 10.83M | 19.09M | 17.50M | 33.60M | 29.13M | 33.76M | 29.36M | 33.04M |
| Operating Income | 715.00K | -2.75M | -18.00K | 1.05M | -3.67M | -5.85M | -6.99M | -11.39M | -13.88M | -14.28M | -20.87M | -20.08M | -14.45M | -23.56M | -17.26M | -18.84M | -6.45M |
| Net Income | 596.00K | -1.53M | 109.00K | 617.00K | -4.34M | -17.28M | -5.37M | -11.55M | -5.06M | 62.72M | -19.71M | -11.90M | -15.17M | -23.18M | -18.71M | -23.46M | -11.21M |
| Diluted EPS | 0.03 | -0.09 | 0.01 | 0.03 | -0.40 | -1.03 | 0.24 | -0.15 | -0.17 | 1.83 | -0.58 | -0.35 | -0.44 | -0.67 | -0.54 | - | - |
| R&D Expense | 2.08M | 1.85M | 1.20M | 1.33M | 1.26M | 1.42M | 2.16M | 1.03M | 1.94M | 2.55M | 3.73M | 3.92M | 4.32M | 4.54M | 5.44M | 5.08M | 3.37M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Sep 2018 | Dec 2018 | Mar 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 27.79M | 28.24M | 28.18M | 33.18M | 24.83M | 31.45M | 35.11M | 30.99M | 113.17M | 95.93M | 91.86M | 84.75M | 74.11M | 68.72M | 51.77M | 79.24M | 64.84M | 66.84M |
| Total Equity | 20.22M | 21.03M | 21.77M | 22.12M | 22.89M | 19.07M | 1.50M | 23.40M | 26.22M | 22.03M | 90.60M | 87.18M | 82.83M | 71.26M | 63.72M | 53.70M | 37.58M | 26.70M | 14.21M | 14.54M |
| Cash & Equivalents | 2.56M | 2.15M | 3.83M | 4.88M | 4.16M | 7.92M | 5.73M | 11.80M | 14.46M | 9.95M | 40.66M | 16.60M | 32.41M | 58.81M | 41.91M | 30.87M | 10.19M | 43.65M | 31.74M | 31.74M |
| Long Term Debt | - | - | - | - | - | 3.19M | - | 2.93M | 2.69M | 2.46M | - | 0 | - | - | - | - | 0 | 33.19M | 33.89M | 34.85M |
| Total Liabilities | - | - | 6.02M | 6.12M | 5.29M | 11.85M | 20.14M | 8.04M | 8.89M | 8.96M | 22.58M | 8.75M | 9.03M | 13.49M | 10.25M | 14.71M | 13.98M | 52.32M | 50.51M | 52.01M |
| Current Liabilities | - | - | 1.80M | 2.39M | 1.92M | 2.91M | 3.77M | 4.12M | 5.27M | 5.97M | 22.44M | 8.61M | 8.62M | 12.31M | 9.15M | 13.21M | 11.85M | 12.74M | 10.72M | 11.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -97.00K | -526.00K | 1.90M | 165.00K | -2.54M | -417.00K | -5.79M | -2.84M | -3.70M | -20.88M | -18.48M | -16.07M | -10.45M | -20.28M | -5.25M | -18.05M | -8.00M |
| Investing Cash Flow | -2.46M | 432.00K | -542.00K | -753.00K | -588.00K | -630.00K | -921.00K | -286.00K | -624.00K | 29.30M | 60.54M | -581.00K | -723.00K | -1.01M | 6.73M | -722.00K | -1.11M |
| Financing Cash Flow | 2.15M | 1.68M | -302.00K | -130.00K | 6.89M | -1.14M | 12.78M | 5.71M | -239.00K | -2.49M | 147.00K | -73.00K | 24.00K | 217.00K | 32.17M | 6.75M | 9.58M |
| Capital Expenditure | -2.46M | -201.00K | -542.00K | -753.00K | -588.00K | -630.00K | -421.00K | -286.00K | -624.00K | -363.00K | -1.30M | -581.00K | -723.00K | -1.01M | -533.00K | -722.00K | -1.11M |
| Free Cash Flow | -2.56M | -727.00K | 1.35M | -588.00K | -3.12M | -1.05M | -6.21M | -3.12M | -4.33M | -21.24M | -19.78M | -16.65M | -11.17M | -21.29M | -5.78M | -18.77M | -9.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 44.0% | 41.2% | 42.2% | 41.0% | 38.9% | 32.5% | 42.5% | 58.0% | 68.0% | 65.2% | 67.6% | 63.2% | 69.3% | 65.4% | 64.5% | 61.0% | 62.5% |
| Operating Margin % | 2.7% | -11.4% | -0.1% | 3.8% | -15.5% | -21.1% | -23.7% | -129.2% | -135.7% | -86.0% | -73.9% | -72.5% | -29.8% | -52.9% | -33.0% | -39.2% | -12.2% |
| Net Margin % | 2.2% | -6.3% | 0.4% | 2.2% | -18.3% | -62.4% | -18.2% | -131.0% | -49.5% | 377.7% | -69.8% | -42.9% | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% |
| ROE % | 2.8% | -7.1% | 0.5% | 2.7% | -22.8% | -1,149.1% | -22.9% | -44.0% | -23.0% | 71.9% | -27.7% | -18.7% | -28.3% | -61.7% | -70.1% | -165.1% | -77.1% |
| ROCE % | - | -10.6% | -0.1% | 4.0% | -12.1% | -27.8% | -25.6% | -38.2% | -55.5% | -16.3% | -28.8% | -30.9% | -26.0% | -59.0% | -26.0% | -34.8% | -11.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Royce & Associates LP | 7.77% | 3.27M | $10.02M |
| 2 | Nantahala Capital Management, LLC | 7.76% | 3.27M | $10.01M |
| 3 | Archon Capital Management LLC | 6.28% | 2.64M | $8.09M |
| 4 | Vanguard Capital Management LLC | 3.64% | 1.53M | $4.70M |
| 5 | Essex Investment Management Co LLC | 2.70% | 1.14M | $3.48M |
| 6 | AIGH Capital Management LLC | 2.68% | 1.13M | $3.45M |
| 7 | Silverberg Bernstein Capital Management LLC | 2.47% | 1.04M | $3.18M |
| 8 | Commonwealth Equity Services, LLC | 1.54% | 649.06K | $1.99M |
| 9 | Horizon Kinetics Asset Management LLC | 1.39% | 585.00K | $1.79M |
| 10 | Blackrock Inc. | 1.33% | 560.99K | $1.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APYX
How The Apyx Medical (APYX) Story Is Evolving With New Growth Drivers And Profitability Goals - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNNktaUkhSTFVkRTNtUWpiRG90LXktSzhWR3ZxbDYxakhGZDJpVjBLak1CX3kxMjNPczduZ1lDOFVSdnNNdXlmbUJLLVQwZUdnZS1NcUpra3FYUjRNa3hsN00xak5GTTJ3QVFIUEEtd2F2U2Y4ak82dDY0eFN6N1BGUmlfMjVYT1FkOHZuSm…
Apyx Medical CEO and CFO to Hold Aug. 11 Investor Fireside Chat - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOb2ZnbzFoYnlhRFRVVnVqMGJ3d3lLeHlnVUJvQl85M2R3RHZUZU1mYUdTVkZkT21zUldRZml0VDFBaE5Icmlkck51bWFGOHVSZ2pQNGRLSGE2WnNKOXB3YWFSZkx5dlJiZ3diZXZOdFpYQ2tRdllXYXVMMWtSUXMtZHdxaklhbFQ5RENxND…
Apyx Medical Corporation (APYX) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPOVRRYXhUOHEtMjQ2NkZfLTNYQXMtM3otakNvMU52alVrNTBGVDVXbVFXSXVUWnl6ZlljeXc4SDdtRTNuYzBmdEhNTk5fb2dVa0QycGRBT3Ewd3llaE8xX0ViTFQycEZCVEl6OE9VWG5QU2ZyZUx5bU9SbG1UMUt3RWw2YmdIcWJuU2ZZMF…
APYX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9sZ2cwakt6YWJpVmJwTkNZSklIR19PVktYcEkzZnhoTmRmVnNSd3ZzV09qdFVUUDhnTlBLcVlZZkE2UHVvTHpta2Q3VWZ6Y3hXMldpelJlWTAweTZWVVV6czRaVk5aMV9Obk5DSW9BOW14OFN5NDFoQkhB?oc=5" target="_blank">APY…
Apyx Medical Corporation Reports First Quarter 2026 Financial Results - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQMjZyZFVLdFpZVlRZc2tPS3lsQ0ZxQkwwTmxXOWNuNjRhUXBHQjBsb3Q0UGk2aHVUQlhGZlFoTjYtZjczaWQyVWJQeXZ6MWtUaWpGMTRNeko1OWpQSXM1dXJJZG40Q3lnT0drT3oycjNGMEhUU2U1MXlMVDZ5WFhNZFFnZnVMNFExV1Fxcm…
Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQNFBqM0hldzkycmgtTUhIM09jZUwtREQzWXpWVHV2LV9waGNhaVNEYUU2dzQ4UlNfaXdDd25GbktlLTdXU2IwOWJIcEFDRzNXYndKTFJ2U3VZWnczeU1FNHIwdkZCamhnVTNLa2JoVndteTZXZDV1d2lybDVsVzhjamhQZTlRU0tVTHBlUk…
APYX — Frequently Asked Questions
What is the current share price of Apyx Medical Corporation (APYX)?
As of 2026-09-19 21:16 PDT, Apyx Medical Corporation (APYX) trades at $3.05 on NasdaqGS. Its 52-week range is $1.90 to $4.86.
What is the market capitalisation of APYX?
Apyx Medical Corporation (APYX) has a market capitalisation of $128.48M on NasdaqGS.
What is the P/E ratio of APYX?
APYX trades at a trailing price-to-earnings (P/E) ratio of -15.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 12.06.
What is the return on equity (ROE) of APYX?
APYX has a return on equity (ROE) of -90.69%. Its return on capital employed (ROCE) is -11.69%.
Is APYX a good stock to buy?
This page provides a data-driven analysis of Apyx Medical Corporation (APYX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.